powder mixture the wet granulate mixture was dried in a fluid bed drier at 50 u00b0 c to a loss on drying lod of 0 5 2 0 the resulting dry granulate of high purity torsemide modification ii was then sifted through a 0 8 mm sieve and magnesium stearate nf was added to the milled granulate the final blend of high purity torsemide modification ii excipients and magnesium stearate was compressed into oval shaped tablets on a rotary tableting machine the dissolution method used was the u s p paddle method at 90 rpm with 0 1m kh 2 po 4 ph 4 5 at 37 u00b0 c for the dissolution test 6 tablets were tested in 900 ml of phosphate buffer ph 4 5 according to the paddle method of the u s p examples 3a 3b and 3c show the dissolution rates of three tablet lots directly after production and after 6 weeks of storage at 40 u00b0 c at a relative humidity rh of 75 the dissolution rates of high purity torsemide form ii batch nos k 26056 k 26057 and k 26058 were identical under both conditions there was no substantial change in the dissolution rates of any of the present pharmaceutical formulations containing torsemide modification ii following 6 weeks of the above storage conditions the dissolution method used was the u s p paddle method at 50 rpm with purified water at 37 u00b0 c for the dissolution test 6 tablets were tested in 900 ml of purified water according to the paddle method of the u s p example 4b shows the dissolution rates of one representative tablet lot directly after production and after 3 months of storage at 40 u00b0 c at a.